BMJ Open (Nov 2024)

Development of the Ontario Hereditary Cancer Research Network, a unified registry as a resource for individuals with inherited cancer syndromes: an observational registry creation protocol

  • Vasily Giannakeas,
  • Amanda Smith,
  • Hong Wang,
  • Harriet Feilotter,
  • Melyssa Aronson,
  • Andrea Eisen,
  • Raymond H Kim,
  • Jordan Lerner-Ellis,
  • Steven A Narod,
  • Laszlo Radvanyi,
  • Kathleen Bell,
  • Jane Bayani,
  • Ian King,
  • DAVID MALKIN,
  • Kathy Chun,
  • Irene L Andrulis,
  • Bailey Gallinger,
  • Anita Villani,
  • George Charames,
  • Lincoln Stein,
  • Sarah Sawyer,
  • Karen Panabaker,
  • Philip Awadalla,
  • Trevor Pugh,
  • Mohammad Reza Akbari,
  • Peter Goodhand,
  • Brandon Chan,
  • Yael Silberman,
  • Jennifer Brooks,
  • Melanie Spears,
  • Kirsten M Farncombe,
  • Lauren K Hughes,
  • Elif Tuzlali,
  • Michelle D Brazas,
  • Melissa Cable-Cibula,
  • Melanie Courtot,
  • Jamie Harland,
  • Katie Lark,
  • Ellen MacDougall,
  • Alison Rusnak,
  • Christopher Deutschman,
  • Chiquita Hessels,
  • Brittney Johnstone,
  • Talia Mancuso,
  • Kelly McDonald,
  • Meredith McLaren,
  • Karen Ott,
  • Stephen Parrott,
  • Wendy Parulekar,
  • Aaron Pollet,
  • Laila Schenkel,
  • Larissa Waldman,
  • Martin Yaffe

DOI
https://doi.org/10.1136/bmjopen-2024-087023
Journal volume & issue
Vol. 14, no. 11

Abstract

Read online

Introduction In Canada, care for individuals with hereditary cancer is fragmented across the provinces and territories, with carriers of pathogenic variants in cancer-susceptibility genes seeing multiple doctors and often advocating for their own management plans. The need for a national registry of carriers has been well established. While other cancer consortia exist, barriers in clinical and genomic data sharing limit the utility of the information gathered.Methods and analysis Within the province of Ontario, the Ontario Hereditary Cancer Research Network (OHCRN), funded by and located at the Ontario Institute for Cancer Research, is being developed to fill this gap. The registry will hold clinical, genomic and self-reported data from consented carriers and will make this data available to qualified researchers in anonymised and aggregated form. Individuals must agree to certain components to participate in OHCRN; there are also optional consents participants can agree to without impacting their involvement in OHCRN. We plan to open the registry for participant enrolment in mid-2025.Ethics and dissemination Ethics approval for registry creation was obtained from the Ontario Cancer Research Ethics Board, a centralised body that streamlines reviews for cancer research studies in Ontario. Registry data will be disseminated to participants and researchers as aggregate data through the OHCRN website and presented at scientific conferences, made available to Ontario Health (Cancer Care Ontario) to inform policy and evidence-based practice, as well as be available to the scientific community for further analysis and answering relevant questions.